1
|
Vigario FL, Nagy NA, The MH, Sparrius R, Bouwstra JA, Kros A, Jiskoot W, de Jong EC, Slütter B. THE USE OF A STAGGERED HERRINGBONE MICROMIXER FOR THE PREPARATION OF RIGID LIPOSOMAL FORMULATIONS ALLOWS EFFICIENT ENCAPSULATION OF ANTIGEN AND ADJUVANT. J Pharm Sci 2022; 111:1050-1057. [PMID: 35114210 DOI: 10.1016/j.xphs.2022.01.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 01/27/2022] [Accepted: 01/27/2022] [Indexed: 10/19/2022]
Abstract
Anionic liposomal formulations have previously shown to have intrinsic tolerogenic capacity and these properties have been related to the rigidity of the particles. The combination of highly rigid anionic liposomes to deliver tolerogenic adjuvants and antigen peptides has potential applications for the treatment of autoimmune and inflammatory diseases. However, the preparation of these highly rigid anionic liposomes using traditional methods such as lipid film hydration presents problems in terms of scalability and loading efficiency of some costly tolerogenic adjuvants like 1-α,25-dihydroxyvitaminD3. Here we propose the use of an off-the-shelf staggered herringbone micromixer for the preparation of these formulations and performed a systematic study on the effect of temperature and flow conditions on the size and polydispersity index of the formulations. Furthermore, we show that the system allows for the encapsulations of a wide variety of peptides and significantly higher loading efficiency of 1-α,25-dihydroxyvitaminD3 compared to the traditional lipid film hydration method, without compromising their non-inflammatory interaction with dendritic cells. Therefore, the microfluidics method presented here is a valuable tool for the preparation of highly rigid tolerogenic liposomes in a fast, size-tuneable and scalable manner.
Collapse
Affiliation(s)
- F Lozano Vigario
- Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands
| | - N A Nagy
- Department of Experimental Immunology, Amsterdam University Medical Centre, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, Netherlands
| | - M H The
- Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands
| | - R Sparrius
- Department of Experimental Immunology, Amsterdam University Medical Centre, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, Netherlands
| | - J A Bouwstra
- Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands
| | - A Kros
- Department of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, The Netherlands
| | - W Jiskoot
- Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands
| | - E C de Jong
- Department of Experimental Immunology, Amsterdam University Medical Centre, Amsterdam Institute for Infection & Immunity, University of Amsterdam, Amsterdam, Netherlands
| | - B Slütter
- Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands.
| |
Collapse
|